Inflammatory modulation of the response of bronchial epithelial cells to lipopolysaccharide with pretreatment by montelukast [PDF]
Kragujevac Journal of Science, 2022 Montelukast, a leukotriene receptor antagonist, is the most prescribed nonsteroidal anti-inflammatory drug used as an add-on therapy for asthma. Besides its effect on blocking leukotriene action, montelukast has been proposed to have secondary anti ...
Jendrišek Gorana +2 more
doaj +2 more sources
Sleeptalking! Sleepwalking! Side Effects of Montelukast [PDF]
Case Reports in Pulmonology, 2013 A 16-year-old Caucasian female presented to the pulmonary clinic for a followup on her asthma. Due to the worsening of allergy-related symptoms, therapy with montelukast 10 mg daily was started and resulted in good relief of the patient’s symptoms.
Samer Alkhuja +2 more
doaj +3 more sources
Farmacéuticos Comunitarios, 2014 Introducción: El objetivo de este trabajo es analizar la utilización de montelukast en adultos desde tres farmacias comunitarias. Material y métodos: Estudio descriptivo, observacional en tres farmacias comunitarias (enero 2009 - febrero 2013) en ...
Peris Molina MT +3 more
doaj +2 more sources
Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction. [PDF]
PLoS ONE, 2010 Both fish oil and montelukast have been shown to reduce the severity of exercise-induced bronchoconstriction (EIB). The purpose of this study was to compare the effects of fish oil and montelukast, alone and in combination, on airway inflammation and ...
Sandra Tecklenburg-Lund +5 more
doaj +3 more sources
Skin rash and mild bruising: Is montelukast a safe drug?
Indian Journal of Respiratory Care, 2018 Montelukast is one of the commonly used drugs in asthma patients. It is prescribed along with inhalational corticosteroids. Although a relatively safe drug, there is a probability of occurrence of skin rashes and skin bruising.
Deep Inder +3 more
doaj +2 more sources
Journal of Pharmacological Sciences, 2007 Montelukast, a selective reversible cysteinyl leukotriene D4-receptor (LTD4 receptor) antagonist, is used in the treatment of asthma. We have investigated alterations in the glutathione (GSH) and activity levels of antioxidative enzymes [superoxide ...
Zekai Halici +2 more
exaly +3 more sources
Montelukast Prescription Prevalence and Impact on Clinical Outcomes Among Patients with Asthma: A Cross-Sectional Study in Saudi Arabia [PDF]
Journal of Asthma and AllergyAbdullah A AlqarniAbdulelah M AldhahirRayan A SirajJaber S AlqahtaniRose M AlghamdiThuraya A BaqaisNorah A NajraniAsma Z AlbarqiAhmed H AlasimiHassan AlwafiDepartment of Respiratory Therapy, Faculty of Medical Rehabilitation Sciences, King Abdulaziz ...
Alqarni AA +9 more
doaj +2 more sources
Montelukast promotes mitochondrial biogenesis via CREB/PGC-1α in human bronchial epithelial cells
Artificial Cells, Nanomedicine, and Biotechnology, 2019 Bronchial epithelial mitochondrial dysfunction including impaired mitochondrial biogenesis has been linked with the initiation and development of bronchial asthma.
Huan Wang +4 more
doaj +2 more sources
APPLICATION EFFICIENCY OF MONTELUKAST AMONG CHILDREN SUFFERING FROM BRONCHIAL ASTHMA
Педиатрическая фармакология, 2008 The article provides the results of montelukast efficiency depending on bronchial asthma severity level and the duration of a disease; the assessment of functional figures dynamics, disease pattern before and after the treatment with montelukast and the ...
A.K. Gevorkyan, E.A. Galeeva
doaj +3 more sources
Impact of China's National Volume-Based Procurement Policy on Cost, Volume, and Market Structure: An Interrupted Time-Series Analysis of Montelukast Sodium. [PDF]
Health Care SciUsing ARIMA‐based interrupted time‐series analysis, this study reveals that China's NVBP policy significantly reduced daily costs and enhanced affordability, driving generic substitution and the elimination of low‐quality products. Additionally, non‐winning manufacturers adopted strategic pricing behaviors to segment the market.
Cheng Y +6 more
europepmc +2 more sources